⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 15, 2026HaematologicaOpen Access

Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation

Federica Sora'A. Bacigalupo sabrina giammarco E. Metafuni Filippo Frioni eugenio galli Maria Assunta Limongiello Simona Sica Patrizia Chiusolo

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to assess platelet recovery and its impact on survival in patients with myelofibrosis post-transplant.
Analyzed data from 93 patients with myelofibrosis
Measured platelet counts aiming for 50x10^9/L within day +100 post-transplant
Evaluated non-relapse mortality and actuarial survival rates
67% of patients achieved the target platelet count by day +100
Achieving this platelet count correlated with significantly lower non-relapse mortality (5% vs 55%; p=0.0009)
Patients reaching the target exhibited higher 5-year actuarial survival rates (85% vs 38%)

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Examines platelet recovery and survival outcomes in myelofibrosis patients after allogeneic transplant, indicating long-term mortality implications.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sora' et al. (2026) studied this question.

synapsesocial.com/papers/696b26b2d2a12237a9349ef9 https://doi.org/10.3324/haematol.2025.288371

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Allogeneic hematopoietic stem cell transplantation for myelofibrosis; Patterns, treatment and outcome after relapse and long-term follow up.2025
2The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with MyelofibrosisCohort Study · 2026
3Haplo-identical transplantation in patients with myelofibrosis, a phase 2 prospective multicentric study2025
4[Selected donor CD34(+) cell boosts for salvage treatment of poor graft function following allogeneic hematopoietic stem cell transplantation in primary myelofibrosis: 3 cases report].2024
5Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical ReviewReview · 2016 · 19 citations

More related papers

Early prediction of platelet recovery with immature platelet fraction in patients receiving hematopoietic stem cell transplantation2024
Outcomes of allogeneic haematopoietic cell transplantation for myelofibrosis in children and adolescents: the retrospective study of the EBMT Paediatric Diseases WP2024
Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis2024

More from Haematologica

Venetoclax plus azacitidine in younger adults with acute myeloid leukemia beyond historical comparisons. Comment on: "Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy"Thu,
Effects of secondary factor VIII prophylaxis on joint and bone health in a hemophilia A mouse modelThu,